Avtal | $24,000,000 | (Mar 20, 2026)
games2gether | $5,202,945 | (Mar 20, 2026)
Claros | $30,000,000 | (Mar 20, 2026)
Certified by Founder
Lodge
T-Therapeutics Ltd
start up
United Kingdom
- Cambridge
- 16/11/2023
- Series A
- $59,707,000
T-Therapeutics is a next-generation TCR company, spun out from the University of Cambridge, deeply rooted in world-leading academic science. We are developing ‘optimal’ TCR based therapeutics using our proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs.
We combine world-leading expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration.
- Industry Biotechnology Research
- Website https://t-therapeutics.com/
- LinkedIn https://www.linkedin.com/company/t-therapeutics/about/
Latent | $80,000,000 | (Mar 20, 2026)
Corridor | $25,000,000 | (Mar 20, 2026)
RunSybil | $40,000,000 | (Mar 20, 2026)
Ezra AI Labs | $3,200,000 | (Mar 20, 2026)
Parallel(FRANCE) | $20,000,000 | (Mar 20, 2026)
Health Universe | $6,000,000 | (Mar 20, 2026)
PADO AI | $6,000,000 | (Mar 20, 2026)
Edra | $30,000,000 | (Mar 20, 2026)
Chalkie AI | $4,000,000 | (Mar 20, 2026)
Deeptune | $43,000,000 | (Mar 20, 2026)